Concepedia

Author

Matthias Freiwald

Boehringer Ingelheim (Germany)

Also Known As

C. Schuler, M Freiwald, M. Freiwald, Matthias Freiwald, Stephan Dupke

24

Publications

1K

Citations

14

H-Index

22

Concepts

All Affiliations

Boehringer Ingelheim (Germany)University of WürzburgUniversidad de NavarraKlinik Schillerhöhe
MF

About

Matthias Freiwald is an author at Boehringer Ingelheim (Germany) specializing in medicine, oncology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

169

2

Pharmacology

3

3

83

3

Immunology

2

2

86

4

Biochemistry

1

1

18

5

Pathology

1

1

11

Matthias Freiwald

×

12

Publications

383

Citations

11

H-Index

YearCitations

Understanding Recent Increases in the Incidence of Sexually Transmitted Infections in Men Having Sex With Men: Changes in Risk Behavior From Risk Avoidance to Risk Reduction

Ulrich Marcus, Viviane Bremer, Osamah Hamouda,

Sexually Transmitted Diseases

2005

89

Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression

Marion Wobser, Heike Voigt, Roland Houben,

Cancer Immunology Immunotherapy

2006

75

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

Matthias Freiwald, Ulrike Schmid, Angèle Fleury,

Cancer Chemotherapy and Pharmacology

2014

53

Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model

Matthias Freiwald, Anagnostis Valotis, Andreas Kirschbaum,

Respiratory Research

2005

37

Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis

Ulrike Schmid, Karl‐Heinz Liesenfeld, Angèle Fleury,

Cancer Chemotherapy and Pharmacology

2017

23

Prediction of Neutropenia-Related Effects of a New Combination Therapy With the Anticancer Drugs BI 2536 (a Plk1 Inhibitor) and Pemetrexed

Elena Soto, Alexander Staab, Matthias Freiwald,

Clinical Pharmacology & Therapeutics

2010

18

Methacholine delays pulmonary absorption of inhaled β2-agonists due to competition for organic cation/carnitine transporters

Mirjam Gnadt, Beatrice Trammer, Matthias Freiwald,

Pulmonary Pharmacology & Therapeutics

2012

18

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

Leora Horn, Scott Gettinger, D. Ross Camidge,

Lung Cancer

2017

18

Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

Ulrike Schmid, Benjamin Weber, Céline Sarr,

BMC Pulmonary Medicine

2021

16

Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

Ulrike Schmid, Benjamin Weber, Mats O. Magnusson,

Respiratory Medicine

2021

13

Page 1